RT Journal Article SR Electronic T1 Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1054 OP 1057 DO 10.2967/jnumed.116.180984 VO 58 IS 7 A1 Yusuf Menda A1 Thomas M. O’Dorisio A1 James R. Howe A1 Michael Schultz A1 Joseph S. Dillon A1 David Dick A1 G. Leonard Watkins A1 Timothy Ginader A1 David L. Bushnell A1 John J. Sunderland A1 Gideon K.D. Zamba A1 Michael Graham A1 M. Sue O’Dorisio YR 2017 UL http://jnm.snmjournals.org/content/58/7/1054.abstract AB Localization of the site of the unknown primary tumor is critical for surgical treatment of patients presenting with neuroendocrine tumor (NET) with metastases. Methods: Forty patients with metastatic NET and unknown primary site underwent 68Ga-DOTATOC PET/CT in a single-site prospective study. The 68Ga-DOTATOC PET/CT was considered true-positive if the positive primary site was confirmed by histology or follow-up imaging. The scan was considered false-positive if no primary lesion was found corresponding to the 68Ga-DOTATOC–positive site. All negative scans for primary tumor were considered false-negative. A scan was classified unconfirmed if 68Ga-DOTATOC PET/CT suggested a primary, however, no histology was obtained and imaging follow-up was not confirmatory. Results: The true-positive, false-positive, false-negative, and unconfirmed rates for unknown primary tumor were 38%, 7%, 50%, and 5%, respectively. Conclusion: 68Ga-DOTATOC PET/CT is an effective modality in the localization of unknown primary in patients with metastatic NET.